Beone Medicines Share Price (NASDAQ: ONC)

$313.96

▲

-0.01

(0%)

Live

Last updated on August 23, 2025 at 12:41 AM IST

$₹

Check the interactive Beone Medicines Stock chart to analyse performance

Beone Medicines stock performance

as on August 23, 2025 at 12:41 AM IST

Today's Low:$312.59
Today's High:$316.31
$313.96
0.44%
Downside
Day's Volatility :1.18%
Upside
0.74%
52 Weeks Low:$172.67
52 Weeks High:$330.63
$313.96
45.0%
Downside
52 Weeks Volatility :47.78%
Upside
5.04%

Beone Medicines Stock Returns

Period	Beone Medicines Ltd	Index (Russel 2000)
3 Months	30.03%	0.0%
6 Months	22.93%	0.0%
1 Year	60.47%	0.0%
3 Years	81.44%	-7.7%

Beone Medicines Ltd Key Stats

Check Beone Medicines key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$313.97
Open	$311.5
Today's High	$316.31
Today's Low	$312.59
Market Capitalization	$37.6B
Today's Volume	$159.5K
52 Week High	$330.63
52 Week Low	$172.67
Revenue TTM	$4.6B
EBITDA	$79.2M
Earnings Per Share (EPS)	$-1.7
Profit Margin	-3.89%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-4.98%

Stock Returns calculator for Beone Medicines Stock including INR - Dollar returns

The Beone Medicines stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Beone Medicines investment value today

Current value as on today

₹1,64,768

Returns

₹64,768

(+64.77%)

Returns from Beone Medicines Stock

₹60,487 (+60.49%)

Dollar Returns*

₹4,281 (+4.28%)

Indian investors sentiment towards Beone Medicines Stock

-20%

Period: Jul 22, 2025 to Aug 21, 2025. Change in 30 Days versus previous period

Search interest for Beone Medicines Stock from India on INDmoney has decreased by -20% in the last 30 days, reflecting a downward trend in search activity.

Analyst Recommendation on Beone Medicines Stock

Rating

Trend

Beone Medicines Share Price Target

What analysts predicted

Upside of 13.34%

Target:

$355.84

Current:

$313.96

Beone Medicines share price target is $355.84, a slight Upside of 13.34% compared to current price of $313.96 as per analysts' prediction.

Beone Medicines Stock Insights

Price Movement
In the last 3 months, ONC stock has moved up by 31.5%
Increasing Revenue
Beone Medicines Ltd has shown positive revenue growth over the last two quarters. The company's revenue increased from $1.11 billion to $1.31 billion, reflecting an average increase of 15.1% per quarter.
Increasing Net Profit
Beone Medicines Ltd has shown a strong improvement in its net profit over the last three quarters. The net profit increased from -151.88 million dollars to 94.32 million dollars, marking a significant turnaround. On average, the company has experienced a remarkable increase of about 6078.9% in net profit each quarter.
ONC vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 68.3% return, outperforming this stock by 7.8%
ONC vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 114.2% return, outperforming this stock by 32.7%
Price to Sales
Beone Medicines Ltd has a Price-to-Sales Ratio (P/S Ratio) of 7.4, meaning that investors are willing to pay $7.4 for every $1 of sales the company generates. In comparison, Alnylam Pharmaceuticals, Inc. has a much higher P/S Ratio of 24.6, indicating that investors are willing to pay significantly more for each dollar of sales from Alnylam. This suggests that Beone Medicines is currently viewed as less expensive relative to its sales compared to Alnylam.

Beone Medicines Ltd Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$428.2M	↑ 116.03%
Net Income	$-950.6M	↑ 41.08%
Net Profit Margin	-221.99%	↑ 117.92%

	FY20	Y/Y Change
Revenue	$308.9M	↓ 27.87%
Net Income	$-1.6B	↑ 68.37%
Net Profit Margin	-518.18%	↓ 296.19%

	FY21	Y/Y Change
Revenue	$1.2B	↑ 280.83%
Net Income	$-1.4B	↓ 11.69%
Net Profit Margin	-120.15%	↑ 398.03%

	FY22	Y/Y Change
Revenue	$1.4B	↑ 20.37%
Net Income	$-2.0B	↑ 41.78%
Net Profit Margin	-141.52%	↓ 21.37%

	FY23	Y/Y Change
Revenue	$2.5B	↑ 73.65%
Net Income	$-881.7M	↓ 56.0%
Net Profit Margin	-35.86%	↑ 105.66%

	FY24	Y/Y Change
Revenue	$3.8B	↑ 54.96%
Net Income	$-644.8M	↓ 26.87%
Net Profit Margin	-16.92%	↑ 18.94%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$751.7M	↑ 18.48%
Net Income	$-251.2M	↓ 90.55%
Net Profit Margin	-33.41%	↑ 385.39%

	Q2 FY24	Q/Q Change
Revenue	$929.2M	↑ 23.62%
Net Income	$-120.4M	↓ 52.06%
Net Profit Margin	-12.96%	↑ 20.45%

	Q3 FY24	Q/Q Change
Revenue	$1.0B	↑ 7.8%
Net Income	$-121.4M	↑ 0.78%
Net Profit Margin	-12.12%	↑ 0.84%

	Q4 FY24	Q/Q Change
Revenue	$1.1B	↑ 12.6%
Net Income	$-151.9M	↑ 25.16%
Net Profit Margin	-13.47%	↓ 1.35%

	Q1 FY25	Q/Q Change
Revenue	$1.1B	↓ 0.93%
Net Income	$1.3M	↓ 100.84%
Net Profit Margin	0.11%	↑ 13.58%

	Q2 FY25	Q/Q Change
Revenue	$1.3B	↑ 17.72%
Net Income	$94.3M	↑ 7326.77%
Net Profit Margin	7.17%	↑ 7.06%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-570.3M	↑ 11.94%

	FY20	Y/Y Change
Profit	$-1.1B	↑ 85.28%

	FY21	Y/Y Change
Profit	$-447.9M	↓ 57.62%

	FY22	Y/Y Change
Profit	$-511.1M	↑ 14.11%

	FY23	Y/Y Change
Profit	$2.1B	↓ 506.77%

	FY24	Y/Y Change
Profit	$3.2B	↑ 54.71%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$626.7M	↑ 18.57%

	Q2 FY24	Q/Q Change
Profit	$791.0M	↑ 26.22%

	Q3 FY24	Q/Q Change
Profit	$831.1M	↑ 5.07%

	Q4 FY24	Q/Q Change
Profit	$967.3M	↑ 16.38%

	Q1 FY25	Q/Q Change
Profit	$952.3M	↓ 1.55%

	Q2 FY25	Q/Q Change
Profit	$1.2B	↑ 20.84%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-750.3M	↑ 36.98%
Investing Cash Flow	$554.2M	↓ 186.91%
Financing Cash Flow	$85.7M	↓ 94.93%

	FY20	Y/Y Change
Operating Cash Flow	$-196.2M	↑ 71.07%
Investing Cash Flow	$-484.4M	↓ 671.74%
Financing Cash Flow	$795.4M	↑ 5972.39%

	FY21	Y/Y Change
Operating Cash Flow	$-1.3B	↑ 1.19%
Investing Cash Flow	$640.7M	↓ 120.22%
Financing Cash Flow	$3.6B	↓ 30.1%

	FY22	Y/Y Change
Operating Cash Flow	$-1.5B	↑ 15.24%
Investing Cash Flow	$1.1B	↑ 68.13%
Financing Cash Flow	$-19.0M	↓ 100.52%

	FY23	Y/Y Change
Operating Cash Flow	$-1.2B	↓ 22.66%
Investing Cash Flow	$60.0M	↓ 94.43%
Financing Cash Flow	$416.5M	↓ 2295.34%

	FY24	Y/Y Change
Operating Cash Flow	$-140.6M	↓ 87.85%
Investing Cash Flow	$-548.4M	↓ 1013.86%
Financing Cash Flow	$193.4M	↓ 53.55%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-308.6M	↑ 39.22%
Investing Cash Flow	$-209.8M	↑ 235.28%
Financing Cash Flow	$162.3M	↓ 53.24%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-95.6M	↓ 69.02%
Investing Cash Flow	$-111.0M	↓ 47.09%
Financing Cash Flow	$23.0M	↓ 85.82%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$188.4M	↓ 297.06%
Investing Cash Flow	$-133.9M	↑ 20.58%
Financing Cash Flow	$12.7M	↓ 44.99%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$75.2M	↓ 60.1%
Investing Cash Flow	$-93.6M	↓ 30.08%
Financing Cash Flow	$-4.5M	↓ 135.72%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$44.1M	↓ 41.35%
Investing Cash Flow	$-121.9M	↑ 30.27%
Financing Cash Flow	$-33.8M	↑ 646.78%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$263.6M	↑ 497.97%
Investing Cash Flow	$-66.6M	↓ 45.38%
Financing Cash Flow	$35.0M	↓ 203.69%

Beone Medicines Technicals Summary

Sell

Neutral

Buy

Beone Medicines is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Beone Medicines Ltd Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Beone Medicines Ltd	6.48%	22.93%	60.47%	81.44%	32.24%
Regeneron Pharmaceuticals, Inc.	4.5%	-14.59%	-49.64%	-0.73%	0.56%
Vertex Pharmaceuticals Incorporated	-16.69%	-17.94%	-17.2%	38.81%	48.58%
Alnylam Pharmaceuticals, Inc.	43.34%	86.27%	68.31%	115.22%	254.29%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Beone Medicines Ltd	NA	NA	NA	2.29	-0.05	-0.01	NA	34.32
Regeneron Pharmaceuticals, Inc.	14.9	14.9	1.21	39.42	0.15	0.07	0.0	287.55
Vertex Pharmaceuticals Incorporated	28.01	28.01	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Beone Medicines Ltd	NA	$37.6B	32.24%	NA	-3.89%
Regeneron Pharmaceuticals, Inc.	Buy	$62.6B	0.56%	14.9	31.37%
Vertex Pharmaceuticals Incorporated	Buy	$101.1B	48.58%	28.01	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$60.1B	254.29%	NA	-12.96%

About Beone Medicines Ltd

BeOne Medicines Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; Ociperlimab (BGB-A1217), a TIGIT inhibitor; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines Ltd. in May 2025. BeOne Medicines Ltd. was incorporated in 2010 and is based in Basel, Switzerland.

Organization	Beone Medicines
Employees	11000
CEO	Mr. John V. Oyler
Industry	Miscellaneous

Key Management of Beone Medicines Ltd

Name	Title
Mr. John V. Oyler	Co-Founder, Executive Chairman & CEO
Dr. Xiaobin Wu Ph.D.	President, COO & GM of China
Dr. Xiaodong Wang Ph.D.	Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder
Mr. Aaron Rosenberg	Chief Financial Officer
Mr. Chan Lee	General Counsel & Senior VP
Mr. Wang Lai Ph.D.	Global Head of Research & Development
Mr. Titus B. Ball	VP & Chief Accounting Officer
Mr. Marcello Damiani	Chief Technology Officer
Ms. Liza Heapes	Head of Investor Relations
Ms. Eleanor Duff Ph.D.	Senior VP & Head of Corporate Communications

Important FAQs about investing in ONC Stock from India :

What is Beone Medicines share price today?

Beone Medicines share price today is $313.96 as on August 23, 2025 at 12:41 AM IST. Beone Medicines share today touched a day high of $316.31 and a low of $312.59.

What is the 52 week high and 52 week low for Beone Medicines share?

Beone Medicines share touched a 52 week high of $330.63 and a 52 week low of $172.67. Beone Medicines stock price today i.e. August 23, 2025 at 12:41 AM IST is trending at $313.96, lower by 5.04% versus the 52 week high.

How to invest in Beone Medicines Stock (ONC) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Beone Medicines on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Beone Medicines Shares that will get you 0.0048 shares as per Beone Medicines share price of $313.96 per share as on August 23, 2025 at 12:41 AM IST.

What is the minimum amount required to buy Beone Medicines Stock (ONC) from India?

Indian investors can start investing in Beone Medicines (ONC) shares with as little as ₹87.521 or $1 (as of August 22, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹875.21 in Beone Medicines stock (as per the Rupee-Dollar exchange rate as on August 22, 2025). Based on Beone Medicines share’s latest price of $313.96 as on August 23, 2025 at 12:41 AM IST, you will get 0.0319 shares of Beone Medicines. Learn more about fractional shares .

What are the returns that Beone Medicines has given to Indian investors in the last 5 years?

Beone Medicines stock has given 32.24% share price returns and 18.0% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?

Discover More

Granite Yieldboost Spy
$19.71
+2.87%
Ishares Morningstar Value Etf
$87.74
+1.77%
Ab Tax-aware Short Duration Municipal Etf
$25.24
+0.16%
Graniteshares 2x Long Tsla Daily Etf
$20.23
+10.61%
Alpha Capital Acquisition Co - Class A
$10.31
+0.1%
Netclass Technology
$1.74
-7.45%
Proshares Short Ether Strategy Etf
$7.51
-13.58%
Allspring Utilities And High
$12.04
+0.58%
Webs Defined Volatility Xlc
$24.95
+3.36%

Explore all

Beone Medicines Share Price (NASDAQ: ONC)

Beone Medicines stock performance

Beone Medicines Stock Returns

Beone Medicines Ltd Key Stats

Stock Returns calculator for Beone Medicines Stock including INR - Dollar returns

Indian investors sentiment towards Beone Medicines Stock

Analyst Recommendation on Beone Medicines Stock

Beone Medicines Share Price Target

Beone Medicines Stock Insights

Price Movement

Increasing Revenue

Increasing Net Profit

ONC vs ALNY (1 yr)

ONC vs ALNY (3 yr)

Price to Sales

Beone Medicines Ltd Financials

Beone Medicines Technicals Summary

Beone Medicines Ltd Vs Peers

About Beone Medicines Ltd

Key Management of Beone Medicines Ltd

Important FAQs about investing in ONC Stock from India :

What is Beone Medicines share price today?

What is the 52 week high and 52 week low for Beone Medicines share?

How to invest in Beone Medicines Stock (ONC) from India?

What is the minimum amount required to buy Beone Medicines Stock (ONC) from India?

What are the returns that Beone Medicines has given to Indian investors in the last 5 years?

Discover More